Teicoplanin population pharmacokinetic analysis in hospitalized patients

Therapeutic Drug Monitoring

Volumn 28, Issue 6, 2006, Pages 737-743

  Soy, Dolors ^a,b   López, Ester ^a   Ribas, Josep ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Population pharmacokinetics; Teicoplanin; Therapeutic drug monitoring

Indexed keywords

TEICOPLANIN;

ACCURACY; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; BLOOD SAMPLING; CONFERENCE PAPER; CONTROLLED STUDY; CREATININE CLEARANCE; DEMOGRAPHY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG SURVEILLANCE PROGRAM; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STEADY STATE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DRUG MONITORING; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RETROSPECTIVE STUDIES; TEICOPLANIN;

EID: 33845707881     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000249942.14145.ff     Document Type: Conference Paper

References (36)

1. Glupczynski Y, Lagast H, Van der Auwera P, et al. Clinical evaluation of teicoplanin for therapy of severe infections caused by Gram-positive bacteria. Antimicrob Agents Chemother. 1986;29:52-57.
2. Brogden RN, Peters DH. Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1994;47:823-854.
3. Murphy S, Pinney RJ. Teicoplanin or vancomycin in the treatment of Gram-positive infections? J Clin Pharmacol Ther. 1995;20:5-11.
4. Wilson AP. Comparative safety of teicoplanin and vancomycin. Int J Antimicrob Agents. 1998;10:143-152.
5. Heydorn A, Petersen BO, Duus JO, et al. Biosynthetic studies of the glycopeptide teicoplanin by (1)H and (13)C NMR. J Biol Chem. 2000;275:6201-6206.
6. Sun B, Chen Z, Eggert US, et al. Hybrid glycopeptide antibiotics. J Am Chem Soc. 2001;123:12722-12723.
7. Rowland M. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet. 1990;18:184-209.
8. Barbot A, Venisse N, Rayeh F, et al. Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors. Intensive Care Med. 2003;29:1528-1534.
9. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am. 2003;17:479-501.
10. Wilson AP, Shankar S, Felmingham D, et al. Serum and tissue levels of teicoplanin during cardiac surgery: the effect of a high dose regimen. J Antimicrob Chemother. 1989;23:613-617.
11. Wilson AP, Gaya H. Treatment of endocarditis with teicoplanin: a retrospective analysis of 104 cases. J Antimicrob Chemother. 1996;38:507-521.
12. Schaison G, Graninger W, Bouza E. Teicoplanin in the treatment of serious infection. J Chemother. 2000;12(Suppl 5):26-33.
13. Rice TL. Simplified dosing and monitoring of vancomycin for the burn care clinician. Burns. 1992;18:355-361.
14. Leader WG, Chandler MH, Castiglia M. Pharmacokinetic optimisation of vancomycin therapy. Clin Pharmacokinet. 1995;28:327-342.
15. Pea F, Porreca L, Baraldo M, et al. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemother. 2000;45:329-335.
16. Chambers HF, Kennedy S. Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis. Antimicrob Agents Chemother. 1990;34:510-514.
17. Yu DK, Nordbrock E, Hutcheson SJ, et al. Population pharmacokinetics of teicoplanin in patients with endocarditis. J Pharmacokinet Biopharm. 1995;23:25-39.
18. Lortholary O, Tod M, Rizzo N, et al. Population pharmacokinetic study of teicoplanin in severelyneutropenic patients. Antimicrob Agents Chemother. 1996;40:1242-1247.
19. Tod M, Alet P, Lortholary O, et al. Implementation and evaluation of a stochastic control strategy for individualizing teicoplanin dosage regimen. J Pharmacokinet Biopharm. 1997;25:695-712.
20. Lamont E, Thomson AH, Dawber M, et al. Population Pharmacokinetics of Teicoplanin in Outpatient Home Parenteral Antibiotic Therapy (OHPAT) [Abstract]. Uppsala, Sweden: Population Approach Group in Europe, June 16-18, 2004.
21. MacGowan AP. Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides. Ther Drug Monit. 1998;20:473-477.
22. Pea F, Brollo L, Lugano M, et al. Therapeutic drug monitoring-guided high teicoplanin dosage regimen required to treat a hypoalbuminemic renal transplant patient undergoing continuous venovenous hemofiltration. Ther Drug Monit. 2001;23:587-588.
23. Pea F, Viale P, Candoni A, et al. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages. Clin Pharmacokinet. 2004;43:405-415.
24. Vozeh S, Hillman R, Wandell M, et al. Computer-assisted drug assay interpretation based on Bayesian estimation of individual pharmacokinetics: application to lidocaine. Ther Drug Monit. 1985;7:66-73.
25. Jelliffe RW, Schumitzky A, Van Guilder M, et al. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther Drug Monit. 1993;15:380-393.
26. Chow AW, Azar RM. Glycopeptides and nephrotoxicity. Intensive Care Med. 1994;20(Suppl 4):S23-S29.
27. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
28. Beal SL, Sheiner LB, eds. NONMEM Users Guides. MD: GloboMax, LLC, Maryland, 1989-1998.
29. S-plus 6.1 for Windows Supplement. Seattle: Insightful Corp, 2002.
30. Ette EI, Williams PJ, Kim YH, et al. Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol. 2003;43:610-623.
31. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. Journal of Pharmacokinetics and Biopharmaceutics. 1981;9:503-512.
32. Whitehouse T, Cepeda JA, Shulman R, et al. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. J Antimicrob Chemother. 2005;55:333-340.
33. Smithers JA, Kulmala HK, Thompson GA, et al. Pharmacokinetics of teicoplanin upon multiple-dose intravenous administration of 3, 12, and 30 milligrams per kilogram of body weight to healthy male volunteers. Antimicrob Agents Chemother. 1992;36:115-120.
34. Pea F, Brollo L, Viale P, et al. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. J Antimicrob Chemother. 2003;51:971-975.
35. Bailey EM, Rybak MJ, Kaatz GW. Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin. Antimicrob Agents Chemother. 1991;35:1089-1092.
36. Rybak MJ, Lerner SA, Levine DP, et al. Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis. Antimicrob Agents Chemother. 1991;35:696-700.